Can yervoy dosage be adjusted during treatment?

Can Yervoy dosage be adjusted during treatment?

Yes, doctors adjust Yervoy dosing when patients experience immune-related side effects or when the clinical situation changes. The label allows temporary interruption or permanent discontinuation rather than simple dose reductions.

Why would a doctor lower or stop Yervoy?

Severe immune-related adverse events such as colitis, hepatitis, or endocrinopathies often lead to holding the next dose until symptoms resolve. When toxicity returns to grade 1 or baseline, treatment may resume at the same dose or be stopped permanently if the event was life-threatening.

How does dosing work for melanoma versus other cancers?

In unresectable or metastatic melanoma, the approved schedule is 3 mg/kg every three weeks for up to four doses. In adjuvant melanoma the dose is the same but given for up to three years. In renal-cell carcinoma and microsatellite-unstable colorectal cancer, Yervoy is combined with Opdivo at 1 mg/kg every three weeks for four doses, then Opdivo alone continues.

What happens if treatment is interrupted?

Interruptions of a few weeks are common. When therapy restarts, patients usually receive the remaining planned doses without extending the total number of infusions. If a patient misses several cycles, the oncologist decides whether to resume or switch to another regimen.

Do patients on combination therapy face different rules?

When Yervoy is paired with Opdivo, either drug can be held independently. If Yervoy-related toxicity occurs, the next Yervoy dose is often omitted while Opdivo continues; permanent discontinuation of one or both agents depends on severity and response.

When does the Yervoy patent expire?

Bristol Myers Squibb’s composition-of-matter patent for ipilimumab expires in 2025 in the United States, opening the possibility for biosimilar competition after that date [1].

[1] DrugPatentWatch.com – Yervoy (ipilimumab) patent and exclusivity data